| Last Version Text |
<?xml version="1.0" ?>
<ns0:MeasureDoc xmlns:html="http://www.w3.org/1999/xhtml" xmlns:ns0="http://lc.ca.gov/legalservices/schemas/caml.1#" xmlns:ns3="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" version="1.0" xsi:schemaLocation="http://lc.ca.gov/legalservices/schemas/caml.1# xca.1.xsd">
<ns0:Description>
<ns0:Id>20250SB__003993CHP</ns0:Id>
<ns0:VersionNum>93</ns0:VersionNum>
<ns0:History>
<ns0:Action>
<ns0:ActionText>INTRODUCED</ns0:ActionText>
<ns0:ActionDate>2024-12-03</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>AMENDED_SENATE</ns0:ActionText>
<ns0:ActionDate>2025-02-11</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>AMENDED_ASSEMBLY</ns0:ActionText>
<ns0:ActionDate>2025-05-08</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>AMENDED_ASSEMBLY</ns0:ActionText>
<ns0:ActionDate>2025-06-12</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>AMENDED_ASSEMBLY</ns0:ActionText>
<ns0:ActionDate>2025-09-02</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>PASSED_ASSEMBLY</ns0:ActionText>
<ns0:ActionDate>2025-09-08</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>PASSED_SENATE</ns0:ActionText>
<ns0:ActionDate>2025-09-11</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>ENROLLED</ns0:ActionText>
<ns0:ActionDate>2025-09-13</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>CHAPTERED</ns0:ActionText>
<ns0:ActionDate>2025-10-01</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>APPROVED</ns0:ActionText>
<ns0:ActionDate>2025-10-01</ns0:ActionDate>
</ns0:Action>
<ns0:Action>
<ns0:ActionText>FILED</ns0:ActionText>
<ns0:ActionDate>2025-10-01</ns0:ActionDate>
</ns0:Action>
</ns0:History>
<ns0:LegislativeInfo>
<ns0:SessionYear>2025</ns0:SessionYear>
<ns0:SessionNum>0</ns0:SessionNum>
<ns0:MeasureType>SB</ns0:MeasureType>
<ns0:MeasureNum>39</ns0:MeasureNum>
<ns0:MeasureState>CHP</ns0:MeasureState>
<ns0:ChapterYear>2025</ns0:ChapterYear>
<ns0:ChapterType>CHP</ns0:ChapterType>
<ns0:ChapterSessionNum>0</ns0:ChapterSessionNum>
<ns0:ChapterNum>208</ns0:ChapterNum>
</ns0:LegislativeInfo>
<ns0:AuthorText authorType="LEAD_AUTHOR">Introduced by Senator Weber Pierson</ns0:AuthorText>
<ns0:Authors>
<ns0:Legislator>
<ns0:Contribution>LEAD_AUTHOR</ns0:Contribution>
<ns0:House>SENATE</ns0:House>
<ns0:Name>Weber Pierson</ns0:Name>
</ns0:Legislator>
</ns0:Authors>
<ns0:Title> An act to amend Sections 108980 and 108982 of the Health and Safety Code, relating to public health, and declaring the urgency thereof, to take effect immediately.</ns0:Title>
<ns0:RelatingClause>public health, and declaring the urgency thereof, to take effect immediately</ns0:RelatingClause>
<ns0:GeneralSubject>
<ns0:Subject>Cosmetic safety: vaginal suppositories.</ns0:Subject>
</ns0:GeneralSubject>
<ns0:DigestText>
<html:p>Existing law, beginning on January 1, 2027, prohibits a person or entity from manufacturing, selling, delivering, holding, or offering for sale in commerce any cosmetic product that contains any of several specified intentionally added ingredients, including boric acid, except under specified circumstances.</html:p>
<html:p>This bill would extend that prohibition to January 1, 2035, for vaginal suppositories containing intentionally added boric acid. The bill would require, beginning on January 1, 2027, any vaginal suppository product containing boric acid to include a product label, as defined, warning consumers that the product should not be used during pregnancy and other specified conditions. The bill would also exempt a vaginal suppository product from the above-mentioned prohibitions if the product becomes regulated by the United States Food and Drug
Administration.</html:p>
<html:p>The bill would make related findings and declarations.</html:p>
<html:p>This bill would incorporate additional changes to Section 108980 of the Health and Safety Code proposed by AB 60 to be operative only if this bill and AB 60 are enacted and this bill is enacted last.</html:p>
<html:p>This bill would declare that it is to take effect immediately as an urgency statute.</html:p>
</ns0:DigestText>
<ns0:DigestKey>
<ns0:VoteRequired>TWO_THIRDS</ns0:VoteRequired>
<ns0:Appropriation>NO</ns0:Appropriation>
<ns0:FiscalCommittee>NO</ns0:FiscalCommittee>
<ns0:LocalProgram>NO</ns0:LocalProgram>
</ns0:DigestKey>
<ns0:MeasureIndicators>
<ns0:ImmediateEffect>YES</ns0:ImmediateEffect>
<ns0:ImmediateEffectFlags>
<ns0:Urgency>YES</ns0:Urgency>
<ns0:TaxLevy>NO</ns0:TaxLevy>
<ns0:Election>NO</ns0:Election>
<ns0:UsualCurrentExpenses>NO</ns0:UsualCurrentExpenses>
<ns0:BudgetBill>NO</ns0:BudgetBill>
<ns0:Prop25TrailerBill>NO</ns0:Prop25TrailerBill>
</ns0:ImmediateEffectFlags>
</ns0:MeasureIndicators>
</ns0:Description>
<ns0:Bill id="bill">
<ns0:Preamble>The people of the State of California do enact as follows:</ns0:Preamble>
<ns0:BillSection id="id_B0BA17D6-8F89-4310-949A-4F66E467EAAC">
<ns0:Num>SECTION 1.</ns0:Num>
<ns0:Content>
<html:p>The Legislature finds and declares all of the following:</html:p>
<html:p>
(a)
<html:span class="EnSpace"/>
According to published research from Johns Hopkins University, intravaginal boric acid represents one of the few available options for addressing recurrent vaginal yeast and bacterial infections, including infections caused by azole-resistant Candida and nitroimidazole-resistant Trichomoniasis. Intravaginal boric acid is included in multiple national guidelines for addressing infectious vaginitis, including guidelines issued by the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention.
</html:p>
<html:p>
(b)
<html:span class="EnSpace"/>
Research suggests that intravaginal boric acid is well tolerated for use in addressing recurrent vaginal infections. However, little is known about the safety of intravaginal boric acid use during pregnancy, and animal studies show that high levels of oral exposure are associated with increased risk of birth defects. As a result, guidelines issued by the American College of Obstetricians and Gynecologists and health care professional associations in other countries, including Canada and the United Kingdom, recommend against intravaginal boric acid use during pregnancy, or recommend that persons use reliable contraception while using intravaginal boric acid.
</html:p>
<html:p>
(c)
<html:span class="EnSpace"/>
Existing state law bans, beginning January 1, 2027, the manufacture and sale of any cosmetic product containing specified chemicals
as intentionally added ingredients, including boric acid. Because the use of intravaginal boric acid represents one of the few available options for addressing recurrent vaginal infections, additional time for vaginal suppository products containing intentionally added boric acid is warranted to allow these products time to become regulated as a drug under the United States Food and Drug Administration.
</html:p>
</ns0:Content>
</ns0:BillSection>
<ns0:BillSection id="id_C7C7EB4A-8B04-4999-95F6-95683B61F020">
<ns0:Num>SEC. 2.</ns0:Num>
<ns0:ActionLine action="IS_AMENDED" ns3:href="urn:caml:codes:HSC:caml#xpointer(%2Fcaml%3ALawDoc%2Fcaml%3ACode%2Fcaml%3ALawHeading%5B%40type%3D'DIVISION'%20and%20caml%3ANum%3D'104.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'PART'%20and%20caml%3ANum%3D'3.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'CHAPTER'%20and%20caml%3ANum%3D'14.'%5D%2Fcaml%3ALawSection%5Bcaml%3ANum%3D'108980.'%5D)" ns3:label="fractionType: LAW_SECTION" ns3:type="locator">
Section 108980 of the
<ns0:DocName>Health and Safety Code</ns0:DocName>
is amended to read:
</ns0:ActionLine>
<ns0:Fragment>
<ns0:LawSection id="id_7F141B15-12A8-46DB-8543-ED5D07096AF1">
<ns0:Num>108980.</ns0:Num>
<ns0:LawSectionVersion id="id_C0A9EFA8-0E2B-4869-AC25-1E13FEA2BCC3">
<ns0:Content>
<html:p>
(a)
<html:span class="EnSpace"/>
Commencing January 1, 2025, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
</html:p>
<html:p>
(1)
<html:span class="EnSpace"/>
Dibutyl phthalate (CAS no. 84-74-2).
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
Diethylhexyl phthalate (CAS no. 117-81-7).
</html:p>
<html:p>
(3)
<html:span class="EnSpace"/>
Formaldehyde (CAS no. 50-00-0).
</html:p>
<html:p>
(4)
<html:span class="EnSpace"/>
Paraformaldehyde (CAS no. 30525-89-4).
</html:p>
<html:p>
(5)
<html:span class="EnSpace"/>
Methylene glycol (CAS no. 463-57-0).
</html:p>
<html:p>
(6)
<html:span class="EnSpace"/>
Quaternium-15 (CAS no. 51229-78-8).
</html:p>
<html:p>
(7)
<html:span class="EnSpace"/>
Mercury (CAS no. 7439-97-6).
</html:p>
<html:p>
(8)
<html:span class="EnSpace"/>
Isobutylparaben (CAS no. 4247-02-3).
</html:p>
<html:p>
(9)
<html:span class="EnSpace"/>
Isopropylparaben (CAS no. 4191-73-5).
</html:p>
<html:p>
(10)
<html:span class="EnSpace"/>
m-Phenylenediamine and its salts (CAS no. 108-45-2).
</html:p>
<html:p>
(11)
<html:span class="EnSpace"/>
o-Phenylenediamine and its salts (CAS no. 95-54-5).
</html:p>
<html:p>
(12)
<html:span class="EnSpace"/>
The following per- and polyfluoroalkyl substances (PFAS) and their salts:
</html:p>
<html:p>
(A)
<html:span class="EnSpace"/>
Perfluorooctane sulfonate (PFOS); heptadecafluorooctane-1-sulfonic
acid (CAS no. 1763-23-1).
</html:p>
<html:p>
(B)
<html:span class="EnSpace"/>
Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate (CAS no. 2795-39-3).
</html:p>
<html:p>
(C)
<html:span class="EnSpace"/>
Diethanolamine perfluorooctane sulfonate (CAS 70225-14-8).
</html:p>
<html:p>
(D)
<html:span class="EnSpace"/>
Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate (CAS 29081-56-9).
</html:p>
<html:p>
(E)
<html:span class="EnSpace"/>
Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate (CAS 29457-72-5).
</html:p>
<html:p>
(F)
<html:span class="EnSpace"/>
Perfluorooctanoic acid (PFOA)(CAS no. 335-67-1).
</html:p>
<html:p>
(G)
<html:span class="EnSpace"/>
Ammonium pentadecafluorooctanoate (CAS no. 3825-26-1).
</html:p>
<html:p>
(H)
<html:span class="EnSpace"/>
Nonadecafluorodecanoic acid (CAS no. 355-76-2).
</html:p>
<html:p>
(I)
<html:span class="EnSpace"/>
Ammonium nonadecafluorodecanoate (CAS no. 3108-42-7).
</html:p>
<html:p>
(J)
<html:span class="EnSpace"/>
Sodium nonadecafluorodecanoate (CAS no. 3830-45-3).
</html:p>
<html:p>
(K)
<html:span class="EnSpace"/>
Perfluorononanoic acid (PFNA)(CAS no. 375-95-1).
</html:p>
<html:p>
(L)
<html:span class="EnSpace"/>
Sodium heptadecafluorononanoate (CAS no. 21049-39-8).
</html:p>
<html:p>
(M)
<html:span class="EnSpace"/>
Ammonium perfluorononanoate (CAS no. 4149-60-4).
</html:p>
<html:p>
(b)
<html:span class="EnSpace"/>
Except as provided in paragraph (2) of subdivision (e), commencing January 1, 2027, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any
of the following intentionally added ingredients:
</html:p>
<html:p>
(1)
<html:span class="EnSpace"/>
Lily aldehyde (CAS no. 80-54-6).
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
Acetaldehyde (CAS no. 75-07-0).
</html:p>
<html:p>
(3)
<html:span class="EnSpace"/>
Cyclohexylamine (CAS no. 108-91-8).
</html:p>
<html:p>
(4)
<html:span class="EnSpace"/>
Cyclotetrasiloxane (CAS no. 556-67-2).
</html:p>
<html:p>
(5)
<html:span class="EnSpace"/>
Phytonadione (CAS no. 84-80-0).
</html:p>
<html:p>
(6)
<html:span class="EnSpace"/>
Sodium perborate (CAS no. 15120-21-5).
</html:p>
<html:p>
(7)
<html:span class="EnSpace"/>
Styrene (CAS no. 100-42-5).
</html:p>
<html:p>
(8)
<html:span class="EnSpace"/>
Trichloroacetic acid (CAS no. 76-03-9).
</html:p>
<html:p>
(9)
<html:span class="EnSpace"/>
Tricresyl phosphate (CAS no. 1330-78-5).
</html:p>
<html:p>
(10)
<html:span class="EnSpace"/>
Vinyl acetate (CAS no. 108-05-4).
</html:p>
<html:p>
(11)
<html:span class="EnSpace"/>
2-Chloracetamide (CAS no. 79-07-2).
</html:p>
<html:p>
(12)
<html:span class="EnSpace"/>
Allyl isothiocyanate (CAS no. 57-06-7).
</html:p>
<html:p>
(13)
<html:span class="EnSpace"/>
Anthraquinone (CAS no. 84-65-1).
</html:p>
<html:p>
(14)
<html:span class="EnSpace"/>
Malachite green (CAS no. 569-64-2).
</html:p>
<html:p>
(15)
<html:span class="EnSpace"/>
Oil from the seeds of Laurus nobilis L. (CAS no. 84603-73-6).
</html:p>
<html:p>
(16)
<html:span class="EnSpace"/>
Pyrogallol (CAS no. 87-66-1).
</html:p>
<html:p>
(17)
<html:span class="EnSpace"/>
C.I. disperse blue 1 (CAS no. 2475-45-8).
</html:p>
<html:p>
(18)
<html:span class="EnSpace"/>
Trisodium nitrilotriacetate (CAS no. 5064-31-3).
</html:p>
<html:p>
(19)
<html:span class="EnSpace"/>
The following boron substances:
</html:p>
<html:p>
(A)
<html:span class="EnSpace"/>
Perboric acids:
</html:p>
<html:p>
(i)
<html:span class="EnSpace"/>
Sodium salt (CAS no. 11138-47-9).
</html:p>
<html:p>
(ii)
<html:span class="EnSpace"/>
Sodium salt, monohydrate (CAS no. 12040-72-1).
</html:p>
<html:p>
(iii)
<html:span class="EnSpace"/>
Sodium perborate monohydrate (CAS no. 10332-33-9).
</html:p>
<html:p>
(B)
<html:span class="EnSpace"/>
Boric acid (CAS nos. 10043-35-3 and 11113-50-1).
</html:p>
<html:p>
(C)
<html:span class="EnSpace"/>
Borates, tetraborates, octaborates, and boric acid salts and esters, including all of the following:
</html:p>
<html:p>
(i)
<html:span class="EnSpace"/>
Disodium octaborate anhydrous (CAS no. 12008-41-2).
</html:p>
<html:p>
(ii)
<html:span class="EnSpace"/>
Disodium octaborate tetrahydrate (CAS no. 12280-03-4).
</html:p>
<html:p>
(iii)
<html:span class="EnSpace"/>
2-Aminoethanol, monoester with boric acid (CAS no. 10377-81-8).
</html:p>
<html:p>
(iv)
<html:span class="EnSpace"/>
2-Hydroxypropyl ammonium dihydrogen orthoborate (CAS no. 68003-13-4).
</html:p>
<html:p>
(v)
<html:span class="EnSpace"/>
Potassium borate, boric acid potassium salt (CAS no. 12712-38-8).
</html:p>
<html:p>
(vi)
<html:span class="EnSpace"/>
Trioctyldodecyl borate.
</html:p>
<html:p>
(vii)
<html:span class="EnSpace"/>
Zinc borate (CAS no. 1332-07-6).
</html:p>
<html:p>
(viii)
<html:span class="EnSpace"/>
Sodium
borate, disodium tetraborate anhydrous; boric acid, sodium salt (CAS no. 1330-43-4).
</html:p>
<html:p>
(ix)
<html:span class="EnSpace"/>
Tetraboron disodium heptaoxide, hydrate (CAS no. 12267-73-1).
</html:p>
<html:p>
(x)
<html:span class="EnSpace"/>
Orthoboric acid, sodium salt (CAS no. 13840-56-7).
</html:p>
<html:p>
(xi)
<html:span class="EnSpace"/>
Disodium tetraborate decahydrate; borax decahydrate (CAS no. 1303-96-4).
</html:p>
<html:p>
(xii)
<html:span class="EnSpace"/>
Disodium tetraborate pentahydrate; borax pentahydrate (CAS no. 12179-04-3).
</html:p>
<html:p>
(20)
<html:span class="EnSpace"/>
C.I. disperse blue 3 (CAS no. 2475-46-9).
</html:p>
<html:p>
(21)
<html:span class="EnSpace"/>
Basic green 1 (CAS no. 633-03-4).
</html:p>
<html:p>
(22)
<html:span class="EnSpace"/>
Basic blue 7 (CAS no.
2390-60-5).
</html:p>
<html:p>
(23)
<html:span class="EnSpace"/>
3(or5)-((4-(benzylmethylamino)phenyl)azo)-1,2 -(or1,4)-dimethyl-1H-1,2,4-triazolium and its salts (CAS nos. 89959-98-8 and 12221-69-1).
</html:p>
<html:p>
(24)
<html:span class="EnSpace"/>
Basic violet 4 (CAS no. 2390-59-2).
</html:p>
<html:p>
(25)
<html:span class="EnSpace"/>
Basic blue 3 (CAS no. 33203-82-6).
</html:p>
<html:p>
(26)
<html:span class="EnSpace"/>
Basic blue 9 (CAS no. 61-73-4).
</html:p>
<html:p>
(c)
<html:span class="EnSpace"/>
If a cosmetic product made through manufacturing processes intended to comply with this chapter contains a technically unavoidable trace quantity of an ingredient listed in subdivision (a) or (b) and that trace quantity stems from impurities of natural or synthetic ingredients, the manufacturing process, storage, or migration
from packaging, that trace quantity shall not cause the cosmetic product to be in violation of this section.
</html:p>
<html:p>
(d)
<html:span class="EnSpace"/>
For purposes of this section, “ingredient” has the same meaning as defined in Section 111791.5.
</html:p>
<html:p>
(e)
<html:span class="EnSpace"/>
(1)
<html:span class="EnSpace"/>
Commencing January 1, 2027, a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) shall include on the product label the following statement: “WARNING: IT IS RECOMMENDED TO CONSULT WITH A DOCTOR BEFORE USE, particularly if you have sensitivity in your lower pelvis or abdomen, a sexually transmitted disease (STD), pelvic inflammatory disease (PID), vaginal bleeding, sores, ulcerations, nausea, fever,
or chills. Do not use on broken or irritated skin. Stop use and contact a doctor if symptoms persist or worsen, or if you experience irritation, burning, bleeding, or cramping. NOT FOR ORAL CONSUMPTION. FOR VAGINAL USE ONLY. DO NOT USE IF PREGNANT, TRYING TO CONCEIVE, OR NURSING. IF YOU BECOME PREGNANT WHILE USING THIS PRODUCT, DISCONTINUE USE IMMEDIATELY. If swallowed, get medical help or contact Poison Control Center immediately. Some boric acid suppository products may break down a
condom—ensure product has completely dissolved before having sex.”
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
Commencing January 1, 2035, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce a vaginal suppository product that contains intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1).
</html:p>
<html:p>
(3)
<html:span class="EnSpace"/>
Paragraphs (1) and (2) shall not apply to a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) if the product becomes regulated as a drug by the United States Food and Drug Administration.
</html:p>
</ns0:Content>
</ns0:LawSectionVersion>
</ns0:LawSection>
</ns0:Fragment>
</ns0:BillSection>
<ns0:BillSection id="id_657B309C-0E49-4014-8AD3-41FDE9588427">
<ns0:Num>SEC. 2.5.</ns0:Num>
<ns0:ActionLine action="IS_AMENDED" ns3:href="urn:caml:codes:HSC:caml#xpointer(%2Fcaml%3ALawDoc%2Fcaml%3ACode%2Fcaml%3ALawHeading%5B%40type%3D'DIVISION'%20and%20caml%3ANum%3D'104.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'PART'%20and%20caml%3ANum%3D'3.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'CHAPTER'%20and%20caml%3ANum%3D'14.'%5D%2Fcaml%3ALawSection%5Bcaml%3ANum%3D'108980.'%5D)" ns3:label="fractionType: LAW_SECTION" ns3:type="locator">
Section 108980 of the
<ns0:DocName>Health and Safety Code</ns0:DocName>
is amended to read:
</ns0:ActionLine>
<ns0:Fragment>
<ns0:LawSection id="id_476625C1-6A7C-4F86-B3D2-52D5B3A764BC">
<ns0:Num>108980.</ns0:Num>
<ns0:LawSectionVersion id="id_C45CC3B9-10FA-4F4A-83CE-81D2022F76CF">
<ns0:Content>
<html:p>
(a)
<html:span class="EnSpace"/>
Commencing January 1, 2025, a person or entity shall not manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
</html:p>
<html:p>
(1)
<html:span class="EnSpace"/>
Dibutyl phthalate (CAS no. 84-74-2).
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
Diethylhexyl phthalate (CAS no. 117-81-7).
</html:p>
<html:p>
(3)
<html:span class="EnSpace"/>
Formaldehyde (CAS no.
50-00-0).
</html:p>
<html:p>
(4)
<html:span class="EnSpace"/>
Paraformaldehyde (CAS no. 30525-89-4).
</html:p>
<html:p>
(5)
<html:span class="EnSpace"/>
Methylene glycol (CAS no. 463-57-0).
</html:p>
<html:p>
(6)
<html:span class="EnSpace"/>
Quaternium-15 (CAS no. 51229-78-8).
</html:p>
<html:p>
(7)
<html:span class="EnSpace"/>
Mercury (CAS no. 7439-97-6).
</html:p>
<html:p>
(8)
<html:span class="EnSpace"/>
Isobutylparaben (CAS no. 4247-02-3).
</html:p>
<html:p>
(9)
<html:span class="EnSpace"/>
Isopropylparaben (CAS no. 4191-73-5).
</html:p>
<html:p>
(10)
<html:span class="EnSpace"/>
m-Phenylenediamine and its salts (CAS no. 108-45-2).
</html:p>
<html:p>
(11)
<html:span class="EnSpace"/>
o-Phenylenediamine and its salts (CAS no. 95-54-5).
</html:p>
<html:p>
(12)
<html:span class="EnSpace"/>
The following per- and polyfluoroalkyl substances (PFAS) and their
salts:
</html:p>
<html:p>
(A)
<html:span class="EnSpace"/>
Perfluorooctane sulfonate (PFOS); heptadecafluorooctane-1-sulfonic acid (CAS no. 1763-23-1).
</html:p>
<html:p>
(B)
<html:span class="EnSpace"/>
Potassium perfluorooctanesulfonate; potassium heptadecafluorooctane-1-sulfonate (CAS no. 2795-39-3).
</html:p>
<html:p>
(C)
<html:span class="EnSpace"/>
Diethanolamine perfluorooctane sulfonate (CAS 70225-14-8).
</html:p>
<html:p>
(D)
<html:span class="EnSpace"/>
Ammonium perfluorooctane sulfonate; ammonium heptadecafluorooctanesulfonate (CAS 29081-56-9).
</html:p>
<html:p>
(E)
<html:span class="EnSpace"/>
Lithium perfluorooctane sulfonate; lithium heptadecafluorooctanesulfonate (CAS 29457-72-5).
</html:p>
<html:p>
(F)
<html:span class="EnSpace"/>
Perfluorooctanoic acid (PFOA)(CAS no. 335-67-1).
</html:p>
<html:p>
(G)
<html:span class="EnSpace"/>
Ammonium pentadecafluorooctanoate (CAS no.
3825-26-1).
</html:p>
<html:p>
(H)
<html:span class="EnSpace"/>
Nonadecafluorodecanoic acid (CAS no. 355-76-2).
</html:p>
<html:p>
(I)
<html:span class="EnSpace"/>
Ammonium nonadecafluorodecanoate (CAS no. 3108-42-7).
</html:p>
<html:p>
(J)
<html:span class="EnSpace"/>
Sodium nonadecafluorodecanoate (CAS no. 3830-45-3).
</html:p>
<html:p>
(K)
<html:span class="EnSpace"/>
Perfluorononanoic acid (PFNA)(CAS no. 375-95-1).
</html:p>
<html:p>
(L)
<html:span class="EnSpace"/>
Sodium heptadecafluorononanoate (CAS no. 21049-39-8).
</html:p>
<html:p>
(M)
<html:span class="EnSpace"/>
Ammonium perfluorononanoate (CAS no. 4149-60-4).
</html:p>
<html:p>
(b)
<html:span class="EnSpace"/>
Except as provided in paragraph (2) of
subdivision (f), commencing January 1, 2027, no person or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce any cosmetic product that contains any of the following intentionally added ingredients:
</html:p>
<html:p>
(1)
<html:span class="EnSpace"/>
Lily aldehyde (CAS no. 80-54-6).
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
Acetaldehyde (CAS no. 75-07-0).
</html:p>
<html:p>
(3)
<html:span class="EnSpace"/>
Cyclohexylamine (CAS no. 108-91-8).
</html:p>
<html:p>
(4)
<html:span class="EnSpace"/>
Cyclotetrasiloxane (CAS no. 556-67-2).
</html:p>
<html:p>
(5)
<html:span class="EnSpace"/>
Phytonadione (CAS no. 84-80-0).
</html:p>
<html:p>
(6)
<html:span class="EnSpace"/>
Sodium perborate (CAS no. 15120-21-5).
</html:p>
<html:p>
(7)
<html:span class="EnSpace"/>
Styrene (CAS no. 100-42-5).
</html:p>
<html:p>
(8)
<html:span class="EnSpace"/>
Trichloroacetic acid (CAS no. 76-03-9).
</html:p>
<html:p>
(9)
<html:span class="EnSpace"/>
Tricresyl phosphate (CAS no. 1330-78-5).
</html:p>
<html:p>
(10)
<html:span class="EnSpace"/>
Vinyl acetate (CAS no. 108-05-4).
</html:p>
<html:p>
(11)
<html:span class="EnSpace"/>
2-Chloracetamide (CAS no. 79-07-2).
</html:p>
<html:p>
(12)
<html:span class="EnSpace"/>
Allyl isothiocyanate (CAS no. 57-06-7).
</html:p>
<html:p>
(13)
<html:span class="EnSpace"/>
Anthraquinone (CAS no. 84-65-1).
</html:p>
<html:p>
(14)
<html:span class="EnSpace"/>
Malachite green (CAS no. 569-64-2).
</html:p>
<html:p>
(15)
<html:span class="EnSpace"/>
Oil from the seeds of Laurus nobilis L. (CAS no. 84603-73-6).
</html:p>
<html:p>
(16)
<html:span class="EnSpace"/>
Pyrogallol (CAS no. 87-66-1).
</html:p>
<html:p>
(17)
<html:span class="EnSpace"/>
C.I. disperse blue 1 (CAS
no. 2475-45-8).
</html:p>
<html:p>
(18)
<html:span class="EnSpace"/>
Trisodium nitrilotriacetate (CAS no. 5064-31-3).
</html:p>
<html:p>
(19)
<html:span class="EnSpace"/>
The following boron substances:
</html:p>
<html:p>
(A)
<html:span class="EnSpace"/>
Perboric acids:
</html:p>
<html:p>
(i)
<html:span class="EnSpace"/>
Sodium salt (CAS no. 11138-47-9).
</html:p>
<html:p>
(ii)
<html:span class="EnSpace"/>
Sodium salt, monohydrate (CAS no. 12040-72-1).
</html:p>
<html:p>
(iii)
<html:span class="EnSpace"/>
Sodium perborate monohydrate (CAS no. 10332-33-9).
</html:p>
<html:p>
(B)
<html:span class="EnSpace"/>
Boric acid (CAS nos. 10043-35-3 and 11113-50-1).
</html:p>
<html:p>
(C)
<html:span class="EnSpace"/>
Borates, tetraborates, octaborates, and boric acid salts and esters, including all of the following:
</html:p>
<html:p>
(i)
<html:span class="EnSpace"/>
Disodium octaborate anhydrous (CAS no. 12008-41-2).
</html:p>
<html:p>
(ii)
<html:span class="EnSpace"/>
Disodium octaborate tetrahydrate (CAS no. 12280-03-4).
</html:p>
<html:p>
(iii)
<html:span class="EnSpace"/>
2-Aminoethanol, monoester with boric acid (CAS no. 10377-81-8).
</html:p>
<html:p>
(iv)
<html:span class="EnSpace"/>
2-Hydroxypropyl ammonium dihydrogen orthoborate (CAS no. 68003-13-4).
</html:p>
<html:p>
(v)
<html:span class="EnSpace"/>
Potassium borate, boric acid potassium salt (CAS no. 12712-38-8).
</html:p>
<html:p>
(vi)
<html:span class="EnSpace"/>
Trioctyldodecyl borate.
</html:p>
<html:p>
(vii)
<html:span class="EnSpace"/>
Zinc borate (CAS no. 1332-07-6).
</html:p>
<html:p>
(viii)
<html:span class="EnSpace"/>
Sodium borate, disodium tetraborate anhydrous; boric acid, sodium salt (CAS no. 1330-43-4).
</html:p>
<html:p>
(ix)
<html:span class="EnSpace"/>
Tetraboron disodium heptaoxide, hydrate (CAS no. 12267-73-1).
</html:p>
<html:p>
(x)
<html:span class="EnSpace"/>
Orthoboric acid, sodium salt (CAS no. 13840-56-7).
</html:p>
<html:p>
(xi)
<html:span class="EnSpace"/>
Disodium tetraborate decahydrate; borax decahydrate (CAS no. 1303-96-4).
</html:p>
<html:p>
(xii)
<html:span class="EnSpace"/>
Disodium tetraborate pentahydrate; borax pentahydrate (CAS no. 12179-04-3).
</html:p>
<html:p>
(20)
<html:span class="EnSpace"/>
C.I. disperse blue 3 (CAS no. 2475-46-9).
</html:p>
<html:p>
(21)
<html:span class="EnSpace"/>
Basic green 1 (CAS no. 633-03-4).
</html:p>
<html:p>
(22)
<html:span class="EnSpace"/>
Basic blue 7 (CAS no. 2390-60-5).
</html:p>
<html:p>
(23)
<html:span class="EnSpace"/>
3(or5)-((4-(benzylmethylamino)phenyl)azo)-1,2 -(or1,4)-dimethyl-1H-1,2,4-triazolium and its salts (CAS nos. 89959-98-8 and 12221-69-1).
</html:p>
<html:p>
(24)
<html:span class="EnSpace"/>
Basic violet 4 (CAS no. 2390-59-2).
</html:p>
<html:p>
(25)
<html:span class="EnSpace"/>
Basic blue 3 (CAS no. 33203-82-6).
</html:p>
<html:p>
(26)
<html:span class="EnSpace"/>
Basic blue 9 (CAS no. 61-73-4).
</html:p>
<html:p>
(27)
<html:span class="EnSpace"/>
Musk ambrette (CAS no. 83-66-9).
</html:p>
<html:p>
(28)
<html:span class="EnSpace"/>
Musk tibetene (CAS no.145-39-1).
</html:p>
<html:p>
(29)
<html:span class="EnSpace"/>
Musk moskene (CAS no. 116-66-5).
</html:p>
<html:p>
(30)
<html:span class="EnSpace"/>
Musk xylene (CAS no. 81-15-2).
</html:p>
<html:p>
(c)
<html:span class="EnSpace"/>
(1)
<html:span class="EnSpace"/>
Commencing January 1, 2027, a person or entity shall not manufacture, sell, deliver, hold, or offer for sale in commerce a
cosmetic product that contains more than 1.4 percent in fine fragrance products, 0.56 percent in eau de toilette, 0 percent in oral products, and 0.042 percent in all other products of musk ketone (CAS no. 81-14-1).
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
“Oral products” means a cosmetic product that is intended to be applied on teeth or the mucous membranes of the oral cavity.
</html:p>
<html:p>
(d)
<html:span class="EnSpace"/>
If a cosmetic product made through manufacturing processes intended to comply with this chapter contains a technically unavoidable trace quantity of an ingredient listed in subdivision (a) or (b) and that trace quantity stems from
impurities of natural or synthetic ingredients, the manufacturing process, storage, or migration from packaging, that trace quantity shall not cause the cosmetic product to be in violation of this section.
</html:p>
<html:p>
(e)
<html:span class="EnSpace"/>
For purposes of this section, “ingredient” has the same meaning as defined in Section 111791.5.
</html:p>
<html:p>
(f)
<html:span class="EnSpace"/>
(1)
<html:span class="EnSpace"/>
Commencing January 1, 2027, a person or entity that manufactures, sells, delivers, holds, or offers for sale in commerce a vaginal suppository product containing intentionally added boric acid
(CAS nos. 10043-35-3 and 11113-50-1) shall include on the product label the following statement: “WARNING: IT IS RECOMMENDED TO CONSULT WITH A DOCTOR BEFORE USE, particularly if you have sensitivity in your lower pelvis or abdomen, a sexually transmitted disease (STD), pelvic inflammatory disease (PID), vaginal bleeding, sores, ulcerations, nausea, fever, or chills. Do not use on broken or irritated skin. Stop use and contact a doctor if symptoms persist or worsen, or if you experience irritation, burning, bleeding, or cramping. NOT FOR ORAL CONSUMPTION. FOR VAGINAL USE ONLY. DO NOT USE IF PREGNANT, TRYING TO CONCEIVE, OR NURSING. IF YOU BECOME PREGNANT WHILE USING THIS PRODUCT, DISCONTINUE USE IMMEDIATELY. If swallowed, get medical help or contact Poison Control Center immediately. Some boric acid suppository products may break down a condom—ensure product has completely dissolved before having sex.”
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
Commencing January 1, 2035, no person
or entity shall manufacture, sell, deliver, hold, or offer for sale in commerce a vaginal suppository product that contains intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1).
</html:p>
<html:p>
(3)
<html:span class="EnSpace"/>
Paragraphs (1) and (2) shall not apply to a vaginal suppository product containing intentionally added boric acid (CAS nos. 10043-35-3 and 11113-50-1) if the product becomes regulated as a drug by the United States Food and Drug Administration.
</html:p>
</ns0:Content>
</ns0:LawSectionVersion>
</ns0:LawSection>
</ns0:Fragment>
</ns0:BillSection>
<ns0:BillSection id="id_237AED70-6D78-4C8A-AAFA-7E715E1B58B5">
<ns0:Num>SEC. 3.</ns0:Num>
<ns0:ActionLine action="IS_AMENDED" ns3:href="urn:caml:codes:HSC:caml#xpointer(%2Fcaml%3ALawDoc%2Fcaml%3ACode%2Fcaml%3ALawHeading%5B%40type%3D'DIVISION'%20and%20caml%3ANum%3D'104.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'PART'%20and%20caml%3ANum%3D'3.'%5D%2Fcaml%3ALawHeading%5B%40type%3D'CHAPTER'%20and%20caml%3ANum%3D'14.'%5D%2Fcaml%3ALawSection%5Bcaml%3ANum%3D'108982.'%5D)" ns3:label="fractionType: LAW_SECTION" ns3:type="locator">
Section 108982 of the
<ns0:DocName>Health and Safety Code</ns0:DocName>
is amended to read:
</ns0:ActionLine>
<ns0:Fragment>
<ns0:LawSection id="id_A46AD505-1621-4A87-83F9-D6E74EC61E7E">
<ns0:Num>108982.</ns0:Num>
<ns0:LawSectionVersion id="id_B3110196-0EE3-4F39-8A1F-CECB799784C9">
<ns0:Content>
<html:p>For purposes of this chapter, the following terms have the following definitions:</html:p>
<html:p>
(a)
<html:span class="EnSpace"/>
“Cosmetic product” means an article for retail sale or professional use intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance.
</html:p>
<html:p>
(b)
<html:span class="EnSpace"/>
“Perfluoroalkyl and polyfluoroalkyl substances” or “PFAS” means a class of fluorinated organic chemicals containing at least one fully fluorinated carbon atom.
</html:p>
<html:p>
(c)
<html:span class="EnSpace"/>
“Intentionally added PFAS” means either of the following:
</html:p>
<html:p>
(1)
<html:span class="EnSpace"/>
PFAS chemicals that a manufacturer has intentionally added to a product and that have a functional or technical effect on the product.
</html:p>
<html:p>
(2)
<html:span class="EnSpace"/>
PFAS chemicals that are intentional breakdown products of an added chemical.
</html:p>
<html:p>
(d)
<html:span class="EnSpace"/>
“Product label” means a display of written, printed, or graphic matter upon a cosmetic product or upon its immediate container.
</html:p>
</ns0:Content>
</ns0:LawSectionVersion>
</ns0:LawSection>
</ns0:Fragment>
</ns0:BillSection>
<ns0:BillSection id="id_2D072C6E-7699-4E1D-A1FD-BA4342B652DD">
<ns0:Num>SEC. 4.</ns0:Num>
<ns0:Content>
<html:p>Section 2.5 of this bill incorporates amendments to Section 108980 of the Health and Safety Code proposed by both this bill and Assembly Bill 60. That section of this bill shall only become operative if (1) both bills are enacted and become effective on or before January 1, 2026, but this bill becomes operative first, (2) each bill amends Section 108980 of the Health and Safety Code, and (3) this bill is enacted after Assembly Bill 60, in which case Section 108980 of the Health and Safety Code, as amended by Section 2 of this bill, shall remain operative only until the operative date of Assembly
Bill 60, at which time Section 2.5 of this bill shall become operative.</html:p>
</ns0:Content>
</ns0:BillSection>
<ns0:BillSection id="id_6347C3C7-039A-4956-9730-6B653146B1AE">
<ns0:Num>SEC. 5.</ns0:Num>
<ns0:Content>
<html:p>This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety within the meaning of Article IV of the California Constitution and shall go into immediate effect. The facts constituting the necessity are:</html:p>
<html:p>In order for women in this state to have necessary medical and hygiene materials available to them in a timely manner, it is necessary that this act take effect immediately.</html:p>
</ns0:Content>
</ns0:BillSection>
</ns0:Bill>
</ns0:MeasureDoc>
|